NICE to Charge up to $282,000 for New Drug Assessments

The UK’s National Institute of Health and Care Excellence (NICE) plans to start charging pharmaceutical companies new fees for each cost-effectiveness assessment for a new medicine beginning next year. The new fees could be up to $282,000! Find out more here. (Source: Zachary Brennan, RAPS, 10/3/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… July 22, 2019
Officials: FDA Developing Guidance on RWD Quality September 10, 2019
FDA to Use 3-Step Approach in RWE Initiative December 7, 2018
PhRMA Foundation to Fund New Centers of Excellence February 11, 2019
Gottlieb Touts Potential of RWE, RWD January 30, 2019
New Non-Profit Association Launches Free Guideline… January 16, 2019
Sharpless Looks to Keep FDA on Current Track May 4, 2019